DexCom, Inc. (NASDAQ:DXCM) Shares Purchased by Oppenheimer & Co. Inc.

Oppenheimer & Co. Inc. boosted its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 0.8% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 34,594 shares of the medical device company’s stock after acquiring an additional 285 shares during the period. Oppenheimer & Co. Inc.’s holdings in DexCom were worth $3,922,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Team Hewins LLC raised its position in shares of DexCom by 3.4% during the 1st quarter. Team Hewins LLC now owns 2,555 shares of the medical device company’s stock worth $354,000 after purchasing an additional 83 shares during the last quarter. Bleakley Financial Group LLC raised its holdings in shares of DexCom by 1.3% in the first quarter. Bleakley Financial Group LLC now owns 6,856 shares of the medical device company’s stock worth $951,000 after acquiring an additional 87 shares during the last quarter. Capital Insight Partners LLC raised its holdings in shares of DexCom by 2.5% in the second quarter. Capital Insight Partners LLC now owns 3,690 shares of the medical device company’s stock worth $418,000 after acquiring an additional 90 shares during the last quarter. Gulf International Bank UK Ltd lifted its position in shares of DexCom by 0.3% in the first quarter. Gulf International Bank UK Ltd now owns 32,075 shares of the medical device company’s stock valued at $4,448,000 after acquiring an additional 93 shares in the last quarter. Finally, EverSource Wealth Advisors LLC boosted its stake in shares of DexCom by 10.1% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the medical device company’s stock valued at $133,000 after acquiring an additional 98 shares during the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on DXCM. Barclays cut their target price on shares of DexCom from $138.00 to $113.00 and set an “equal weight” rating for the company in a research note on Monday, July 29th. Redburn Atlantic started coverage on shares of DexCom in a research report on Thursday, May 30th. They set a “neutral” rating and a $130.00 target price on the stock. Stifel Nicolaus boosted their price target on DexCom from $90.00 to $100.00 and gave the company a “buy” rating in a report on Friday, August 23rd. Piper Sandler restated an “overweight” rating and set a $90.00 price objective on shares of DexCom in a report on Monday, August 26th. Finally, StockNews.com lowered DexCom from a “buy” rating to a “hold” rating in a research note on Monday, June 10th. Seven equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, DexCom has a consensus rating of “Moderate Buy” and a consensus price target of $112.25.

Insider Activity at DexCom

In other DexCom news, EVP Michael Jon Brown sold 659 shares of the stock in a transaction that occurred on Friday, June 28th. The shares were sold at an average price of $114.29, for a total value of $75,317.11. Following the completion of the sale, the executive vice president now owns 66,901 shares of the company’s stock, valued at $7,646,115.29. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other DexCom news, EVP Sadie Stern sold 426 shares of the company’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the transaction, the executive vice president now directly owns 75,451 shares of the company’s stock, valued at approximately $5,217,436.65. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Michael Jon Brown sold 659 shares of the firm’s stock in a transaction dated Friday, June 28th. The shares were sold at an average price of $114.29, for a total value of $75,317.11. Following the sale, the executive vice president now owns 66,901 shares of the company’s stock, valued at $7,646,115.29. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 2,483 shares of company stock worth $201,708. 0.30% of the stock is currently owned by company insiders.

DexCom Price Performance

DXCM opened at $69.51 on Friday. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00. The company has a 50 day moving average of $82.36 and a two-hundred day moving average of $111.25. The company has a market cap of $27.85 billion, a P/E ratio of 44.85, a P/E/G ratio of 2.12 and a beta of 1.18. The company has a quick ratio of 2.48, a current ratio of 2.82 and a debt-to-equity ratio of 1.00.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, July 25th. The medical device company reported $0.43 earnings per share for the quarter, topping analysts’ consensus estimates of $0.39 by $0.04. The firm had revenue of $1 billion during the quarter, compared to analysts’ expectations of $1.04 billion. DexCom had a net margin of 16.95% and a return on equity of 31.41%. The firm’s revenue was up 15.3% on a year-over-year basis. During the same period in the prior year, the company earned $0.34 EPS. On average, analysts expect that DexCom, Inc. will post 1.69 earnings per share for the current year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.